NEW YORK--(BUSINESS WIRE)--Deerfield announced a $375 million debt investment in Depomed, Inc. as part of $575 million facility to support Depomed’s $1.05 billion acquisition of the U.S. rights to NUCYNTA® from Janssen Pharmaceuticals. Depomed has announced that the Nucynta transaction will more than double its revenue base and that it is immediately accretive to earnings.
Deerfield will provide a $375 million facility which will accrue interest quarterly and amortize in annual increments from the third through the seventh anniversaries of the closing. The company has the right to prepay the facility in tranches at its discretion.
“The acquisition of NUCYNTA is transformational for Depomed. Our facility has been structured to avoid equity dilution and provide flexible terms for repayment and future acquisitions.” said Alex Karnal, Partner at Deerfield Management.
“We are excited to partner with Deerfield, one of the premier investors that provides growth capital for pharmaceutical firms like Depomed. The facility with Deerfield and Pharmakon allows Depomed to close the Nucynta transaction without dilution to our shareholders while we continue to look for assets to further grow our business,” stated Jim Schoeneck, President and CEO of Depomed.
Depomed is a specialty pharmaceutical company that commercializes products for pain and neurology related disorders. Gralise® (gabapentin) is a once-daily treatment approved for the management of postherpetic neuralgia. CAMBIA® (diclofenac potassium for oral solution) is a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks with or without aura in adults (18 years of age or older). Zipsor® (diclofenac potassium) Liquid Filled Capsules is a non-steroidal anti-inflammatory drug indicated for relief of mild to moderate acute pain in adults. Lazanda® (fentanyl) Nasal Spray is an intranasal fentanyl drug used to manage breakthrough pain in adults (18 years of age or older) who are already routinely taking other opioid pain medicines around-the-clock for cancer pain. Gralise and various partner product candidates are formulated with Depomed's proven, proprietary Acuform® drug delivery technology. Depomed has announced the acquisition of the U.S. rights to the NUCYNTA franchise from Janssen Pharmaceuticals, Inc. which is expected to close in the second quarter of 2015. The NUCYNTA franchise includes NUCYNTA® ER (tapentadol) extended release tablets indicated for the management of pain, including neuropathic pain associated with diabetic peripheral neuropathy (DPN), severe enough to require daily, around-the-clock, long-term opioid treatment, and NUCYNTA® (tapentadol), an immediate release version of tapentadol, for management of moderate to severe acute pain in adults. Additional information about Depomed may be found at www.Depomed.com.
Deerfield is an investment management firm committed to advancing healthcare through investment, information and philanthropy.
For more information, please visit www.deerfield.com.